登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Preoperative vs Postoperative Revascularization in Coronary Heart Disease Patients Undergoing Time-Sensitive Non-Cardiac Surgery (CHRONOS-PCI)
ClinicalTrials.gov 上登记的一项冠心病开放试验,由温州医科大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07175870,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Disease stage beyond surgical indications or estimated life expectancy <1 year
排除标准第 9 条
Karnofsky performance score <60
排除标准第 7 条
Eastern Cooperative Oncology Group (ECOG) performance status >2
排除标准第 8 条
Women who are pregnant, breastfeeding, or planning pregnancy during the study period
排除标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07175870,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years Diagnosis of coronary heart disease with non-emergent indication for PCI confirmed by coronary angiography: Non-ST-elevation acute coronary syndrome (NSTE-ACS) at low or intermediate ischemic risk Chronic coronary syndrome (CCS) with one of the following anatomical characteristics (see Appendix 1 for definition): Moderate or severe stenosis of the left main coronary artery Multivessel disease involving the ostium of the left anterior descending artery Three-vessel disease with ≥70% stenosis in each major epicardial vessel Indication for time-sensitive non-cardiac surgery Planned non-cardiac surgery under general anesthesia in the following surgical departments: thoracic surgery, gastrointestinal surgery, colorectal surgery, hepatobiliary and pancreatic surgery, or gynecology For patients with malignant tumors requiring time-sensitive surgery: written informed consent confirming understanding and acceptance that, if randomized to the "PCI-first" group, their tumor surgery will be delayed until 90±14 days after PCI, with acknowledgement of potential risks (e.g., tumor progression, change in resectability) Ability to understand the study requirements and sign written informed consent in the language provided by the research team排除标准:Exclusion Criteria:
Age >80 years Severe thrombocytopenia (platelet count <50×10⁹/L) Cardiogenic shock, severe heart failure (NYHA class IV, Killip class IV, or LVEF ≤35%), malignant arrhythmias (including cardiac arrest, asystole, ventricular fibrillation, or sustained ventricular tachycardia), or other life-threatening conditions requiring resuscitation Moderate-to-severe valvular heart disease, high-grade atrioventricular block, or other severe cardiac/pulmonary dysfunction incompatible with the planned surgery Planned surgery with extremely high bleeding risk (e.g., intracranial surgery, spinal surgery, retinal surgery) Patients with malignant tumors undergoing non-palliative surgery who are in poor general condition, defined as meeting any of the following: Karnofsky performance score <60 Eastern Cooperative Oncology Group (ECOG) performance status >2 Disease stage beyond surgical indications or estimated life expectancy <1 year Patients requiring emergency or urgent surgery due to critical illness Severe renal dysfunction: serum creatinine >442 μmol/L, GFR ≤30 mL/min/1.73 m², or currently on renal replacement therapy Severe hepatic dysfunction: Child-Pugh class C or higher Severe uncontrolled systemic infection Advanced dementia with significant decline in quality of life requiring full-time care and support Systemic thromboembolic disease (e.g., pulmonary embolism) making surgery unsuitable Women who are pregnant, breastfeeding, or planning pregnancy during the study period Severe, uncontrolled comorbid conditions continuously impairing physiological or psychological function Participation in another clinical study within 3 months prior to enrollment Any condition judged by the investigator to interfere with participation or study conduct
引自 ClinicalTrials.gov, NCT07175870, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07175870,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。